Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Review of the 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (now the Society for Immunotherapy of Cancer) | JOURNAL OF TRANSLATIONAL MEDICINE Site Society for Immunotherapy of Cancer Meeting Summary October 2-4 2010 - Washington D.C. Review of the 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer now the Society for Immunotherapy of Cancer Interaction Innovation Integration Exchange Translation Leadership Guiding cancer immunotherapy from bench to bedside Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer Balwit et al. 2 BioMed Central Balwit et al. Journal of Translational Medicine 2011 9 60 http www.translational-medicine.com content 9 1 60 12 May 2011 Balwit et al. Journal of Translational Medicine 2011 9 60 http www.translational-medicine.eom content 9 1 60 JOURNAL OF TRANSLATIONAL MEDICINE MEETING REPORT Open Access Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer James M Balwit1 Pawel Kalinski2 Vernon K Sondak3 Pierre G Coulie4 Elizabeth M Jaffee5 Thomas F Gajewski1 6 and Francesco M Marincola1 7 Abstract Led by key opinion leaders in the field the 25th Annual Meeting of the International Society for Biological Therapy of Cancer iSBTc recently renamed the Society for Immunotherapy of Cancer SITC provided a scientific platform for 500 attendees to exchange cutting-edge information on basic clinical and translational research in cancer immunology and immunotherapy. The meeting included keynote addresses on checkpoint blockade in cancer therapy and recent advances in therapeutic vaccination against cancer induced by Human Papilloma Virus 16. Participants from 29 countries interacted through oral presentations panel discussions and posters on topics that included dendritic cells and cancer targeted therapeutics and immunotherapy innate adaptive immune interplay in cancer clinical trial endpoints vaccine combinations countering negative regulation immune cell trafficking to tumor microenvironment and adoptive T cell
